We believe in the power of vision. Ocata Therapeutics, Inc. (“Ocata”; OTCBB: OCAT, formerly named Advanced Cell Technology, is a clinical stage biotechnology company focused on the development and commercialization of regenerative medicine and cell therapy technologies. The company’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration and myopic macular degeneration. Ocata’s preclinical programs involve cell therapies for the treatment of other ocular disorders and for diseases outside the field of ophthalmology, including autoimmune, inflammatory and wound healing-related disorders.
Www.ocata.com
